Vitruvian Biomedical
VITRUVIAN BioMedical, Inc is a biotechnology company dedicated to advancing personalized medicine, with a focus on developing diagnostics and therapeutics for Alzheimer's Disease. They aim to provide innovative solutions such as therapeutic vaccines targeting ABeta and TAU, and early detection biomarkers, to improve healthcare outcomes globally.
Industries
Nr. of Employees
small (1-50)
Vitruvian Biomedical
16475 Dallas Parkway | Suite 750, Addison, TX 75001
Products
Gene-based therapeutic vaccine candidate targeting amyloid-beta and tau
A DNA vaccine construct designed to elicit antibodies that reduce accumulation of amyloid-beta and tau proteins; demonstrated reduction of target proteins in transgenic animal studies.
Gene-based vaccine candidate targeting amyloid-beta (IND-referenced)
A DNA vaccine candidate focused on amyloid-beta with IND-related information and reported strong immune responses in non-human primates.
Blood-based diagnostic biomarker assay for early-stage detection
A serum biomarker assay under development reported to show elevated levels in early-stage disease versus non-disease controls and intended to identify candidates for therapeutic intervention.
Gene-based therapeutic vaccine candidate targeting amyloid-beta and tau
A DNA vaccine construct designed to elicit antibodies that reduce accumulation of amyloid-beta and tau proteins; demonstrated reduction of target proteins in transgenic animal studies.
Gene-based vaccine candidate targeting amyloid-beta (IND-referenced)
A DNA vaccine candidate focused on amyloid-beta with IND-related information and reported strong immune responses in non-human primates.
Blood-based diagnostic biomarker assay for early-stage detection
A serum biomarker assay under development reported to show elevated levels in early-stage disease versus non-disease controls and intended to identify candidates for therapeutic intervention.
Services
Structuring and executing exclusive licensing agreements and commercialization collaborations for therapeutic and diagnostic technologies.
Conducting preclinical efficacy and immunogenicity studies in small and large animal models to evaluate vaccine candidates.
Business development, fundraising strategy, and advisory services leveraging management experience in licensing and capital raises.
Structuring and executing exclusive licensing agreements and commercialization collaborations for therapeutic and diagnostic technologies.
Conducting preclinical efficacy and immunogenicity studies in small and large animal models to evaluate vaccine candidates.
Business development, fundraising strategy, and advisory services leveraging management experience in licensing and capital raises.
Expertise Areas
- Alzheimer's disease therapeutics
- DNA vaccine development
- Biomarker discovery and assay development
- Preclinical animal model studies
Key Technologies
- DNA-based vaccines
- Vaccine delivery systems for nucleic acid vaccines
- Transgenic animal disease models
- Non-human primate immunogenicity studies